FDA Approval of Donanemab Marks Major Advance in Alzheimer’s Treatment
July 2, 2024 – The U.S. Food and Drug Administration (FDA) has approved donanemab, a groundbreaking treatment for Alzheimer’s disease. Branded as Kisunla™ (pronounced kih-SUHN-lah) by Eli Lilly, donanemab is an amyloid plaque-targeting therapy for persons living with mild cognitive impairment (MCI) or in the mild dementia stage of Alzheimer’s disease with confirmed amyloid pathology. …
FDA Approval of Donanemab Marks Major Advance in Alzheimer’s Treatment Read More »